PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
The Power of Genuine Networking for Entrepreneurs With OneSixOne Ventures with Pablo Casilimas and Justis Mendez
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 182: Life Sciences Startups and Leadership with Scott Pancoast of Zylo Therapeutics
Through the Lens: From serial entrepreneur to neutral who gets deals done - Focus on Daniel Garrie
Point by Point: The Sale of Dental Practices, Raising Capital and More with Logan Growth Advisors
Disrupting Systemic Economic Injustice in the Startup Ecosystem, with Resilient Ventures' Tom Droege and Keith Daniel
From Accidental Entrepreneur to a $2.5M raise, with Cycle Labs' Josh Owen
The One Reason Startups Fail, with VentureSouth's Charlie Banks
Has the SPAC Bubble Burst? Lessons Learned From the Early Days of SPAC Mania
Healthcare Start-Ups: Keys to Fundraising and Growing Your Company Successfully
The Rare Air of Elevation Oncology: Raising Nearly $200M in 2 Years, with CEO Shawn Leland
The Legal Side of Raising Money: Startup Funding Questions Answered, with Anna Tharrington
Startup CEO Who Coded His Way Out: Rainway’s Andrew Sampson
Committed Capital Podcast: ESG and Asset Management - Challenges and Opportunities
The Fracture Startup Journey: Jumping Off a Cliff to Learn to Fly with Abhi Lokesh
The $200 Million Phone Call.
Raising Over $475M in Biomedical Startups, with Serial Entrepreneur Daniel White
Making Payroll, Raising Capital and the Adrenaline Rush of Being a HealthTech CEO, with Ludi's Gail Peace
Ledgers and Law: Roadblocks Facing the Cannabis Industry
As a testament to the U.S. capital markets’ resilience and ability to adapt, IPOs, debt markets and mergers and acquisitions (and related financings) have shown substantial increases over 2023. Activity to date in 2024...more
In a year marked by rising interest rates and intensified regulatory scrutiny, Dechert stood shoulder-to-shoulder with our private equity and private capital clients, crafting innovative strategies for capital raising and...more
Private markets have shown remarkable resilience and innovation in the face of unprecedented challenges and opportunities in the past few years. From the pandemic to the digital transformation, from the climate crisis to the...more
Private equity was on fire globally, at least until 2023. Fundraising targets got ever larger and deal activity was on a roll. So, what changed and what can both investors and managers expect for 2024? In this episode of...more
In 2023, private equity, mergers and acquisitions and venture capital financings have experienced a slowdown across Canada, on the heels of a historically strong year in 2022. In this post we look specifically at the province...more
During this session, Partner Luc Jansen moderated a panel that provided an overview of the current fundraising market and offered insights into which strategies are yielding successful outcomes....more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include: Investment...more
Many commentators predicted a boom in M&A and initial public offerings (IPOs) in the U.K. in 2020, a year that proved making predictions is a risky business. As we enter 2021, however, there are good reasons to believe that...more
How has COVID-19 impacted Venture Capital investment? Panelists discuss the sectors and industries that have become more attractive since the start of the pandemic, changes and trends in transaction documents of VC deals, the...more
How has COVID-19 impacted Venture Capital investment? Panelists will discuss the sectors and industries that have become more attractive since the start of the pandemic, changes and trends in transaction documents of VC...more
The 2015 IPO market produced 152 IPOs, a disappointing tally that lagged well behind the 244 IPOs in 2014 despite continued strength in the life sciences sector. Setting aside the anomalous years of 2008 and 2009, however,...more